Risk factors for induction failure of standard chemotherapy with anthracycline and cytarabine in acute myeloid leukemia patient

被引：0
|
作者：
Jehn, C. [1 ]
Pannenbeckers, M. [1 ]
Klapproth, A. [1 ]
Dahmash, F. [1 ]
Salwender, H. [1 ]
Singh, A. [1 ]
Shikova, J. [1 ]
Schlichting, Y. [1 ]
Meyer, S. [1 ]
Niggemann, C. [2 ]
Vierbuchen, M. [2 ]
Elmaagacli, A. [1 ]
机构：
[1] Allgemein Krankenhaus St Georg, Hamatol Onkol & Stammzelltransplantat, Hamburg, Germany
[2] Allgemein Krankenhaus St Georg, Pathol, Hamburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P925
引用
收藏
页码：254 / 254
页数：1
相关论文
共 50 条
  • [1] A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy
    Dae-Young Kim
    Je-Hwan Lee
    Sun Jin Sym
    Sung-Cheol Yun
    Jung-Hee Lee
    Sung-Doo Kim
    Yunsuk Choi
    Young-Shin Lee
    Young-Ah Kang
    Mijin Jeon
    Miee Seol
    Kyung-Hwa Lee
    Yeon-Joo Lee
    Kyoo-Hyung Lee
    Annals of Hematology, 2011, 90 : 1283 - 1291
  • [2] A prediction model for complete remission upon reinduction for patients with acute myeloid leukemia after failure of anthracycline and cytarabine standard chemotherapy
    Kim, Dae-Young
    Lee, Je-Hwan
    Sym, Sun Jin
    Yun, Sung-Cheol
    Lee, Jung-Hee
    Kim, Sung-Doo
    Choi, Yunsuk
    Lee, Young-Shin
    Kang, Young-Ah
    Jeon, Mijin
    Seol, Miee
    Lee, Kyung-Hwa
    Lee, Yeon-Joo
    Lee, Kyoo-Hyung
    ANNALS OF HEMATOLOGY, 2011, 90 (11) : 1283 - 1291
  • [3] THE EFFECTS OF EARLY INTENSIFIED INDUCTION CHEMOTHERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA COMPARED TO STANDARD ANTHRACYCLINE PLUS CYTARABINE 3+7 CHEMOTHERAPY
    Kwak, D. -H.
    Yoon, J. -H.
    Kim, H. -J.
    Park, S. -S.
    Lee, S. -E.
    Cho, B. -S.
    Eom, K. -S.
    Kim, Y. -J.
    Lee, S.
    Lee, J. -W.
    Min, W. -S.
    HAEMATOLOGICA, 2017, 102 : 211 - 212
  • [4] ACUTE ANTHRACYCLINE CARDIOTOXICITY IN ACUTE MYELOID LEUKEMIA DURING INDUCTION CHEMOTHERAPY: ROLE OF ECHOCARDIOGRAPHY
    Aggarwal, M.
    Mishra, P.
    Saxena, A.
    Gupta, S.
    Tyagi, S.
    HAEMATOLOGICA, 2015, 100 : 656 - 656
  • [5] Low dose cytarabine with or without anthracycline in the induction treatment of elderly patients with acute myeloid leukemia
    Abu-Taleb, F. M.
    Mansour, O. M.
    Khorshid, O. L. A. M. R.
    Raheem, A. Abdel
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S850 - S850
  • [6] A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia
    Valcarcel, David
    Montesinos, Pau
    Sanchez-Ortega, Isabel
    Brunet, Salut
    Esteve, Jordi
    Martinez-Cuadron, David
    Ribera, Jose M.
    Tormo, Mar
    Bueno, Javier
    Duarte, Rafael
    Llorente, Andres
    Pio Torres, Juan
    Guardia, Ramon
    Sanz, Miguel A.
    Sierra, Jorge
    CANCER, 2012, 118 (02) : 410 - 417
  • [7] Patterns of failure to induction chemotherapy in adult acute lymphoblastic leukemia of standard risk.
    Rodriguez, PW
    Vallejos, C
    Santillana, S
    Carracedo, S
    Perez, C
    Solidoro, A
    BLOOD, 1997, 90 (10) : 3845 - 3845
  • [8] Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)
    Stahl, Maximilian F.
    Giblin, Gerard
    Liu, Yiwen
    DeAngelo, Daniel J.
    Stone, Richard M.
    Winer, Eric S.
    Wadleigh, Martha
    Lindsley, Coleman
    Shimony, Shai
    Copson, Kevin
    Charles, Anne
    Nohria, Anju
    Luskin, Marlise R.
    BLOOD, 2022, 140 : 6067 - 6068
  • [9] Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine
    Wiedower, Eric
    Jamy, Omer
    Martin, Michael G.
    ANTICANCER RESEARCH, 2015, 35 (11) : 6287 - 6290
  • [10] Induction Mortality of Acute Myeloid Leukemia Patients Treated With Purine Analogues-Cytarabine-Anthracycline at General Hospital
    Rios, Adan
    Yohannan, Binoy
    Cervoni-Curet, Frances
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S219 - S219
12345